Glivec® (imatinib) & Tasigna® (nilotinib): Risk of Hepatitis B reactivation

Kadar pengguna: 3 / 5

bintang aktifbintang aktifbintang aktifBintang tidak aktifBintang tidak aktif

Date: 25 April 2016



A Direct Healthcare Professional Communication (DHPC) has been approved by NPCB to inform healthcare professionals of the risk of HBV reactivation in patients who are chronic carriers of this virus after receiving a BCR-ABL tyrosine kinase inhibitor (TKI), such as imatinib and nilotinib. Patients should be tested for hepatitis B infection before initiating treatment with imatinib or nilotinib. Patients currently on imatinib or nilotinib should also have baseline testing for hepatitis B infection. Experts in liver disease and in the treatment of hepatitis B should be consulted in patients with positive hepatitis B serology (including those with active disease). Carriers of HBV who require treatment with imatinib or nilotinib should be closely monitored for signs and symptoms of active hepatitis B infection throughout therapy and for several months following termination of therapy. Please refer to the DHPC issued by Novartis Corporation (M) Sdn. Bhd. for further information.

National Pharmaceutical Regulatory Agency (NPRA)
Lot 36, Jalan Universiti (Jalan Profesor Diraja Ungku Aziz), 46200 Petaling Jaya, Selangor, Malaysia.
  • Email:
  • Phone: +603-7883 5400
  • Fax: +603-7956 2924, +603-7956 7075


The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Mobile Web :

Site Last Modified

  • Last Modified: Jumaat 15 Oktober 2021, 15:58:04.
© Copyright 2018 . All Rights Reserved National Pharmaceutical Regulatory Agency NPRA


Choose Your Language

Menu Utama